A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis.

@article{Wingerchuk2005APS,
  title={A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis.},
  author={Dean M. Wingerchuk and J Lesaux and George P. Rice and Marcelo Kremenchutzky and George Cornell Ebers},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2005},
  volume={76 9},
  pages={1294-6}
}
BACKGROUND Epidemiological and ecological studies suggest links between vitamin D deficiency and increased multiple sclerosis (MS) prevalence. OBJECTIVE To evaluate the safety and tolerability of oral calcitriol therapy in an open label pilot study. METHODS 15 ambulatory patients with relapsing-remitting MS and at least one clinical relapse within the previous 12 months received oral calcitriol (target dose: 2.5 microg/d) for 48 weeks. Dietary calcium was restricted to 800 mg/d. Patients… CONTINUE READING
53 Citations
24 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

phenotype, and risk of multiple sclerosis: case–control study. BMJ 2003;327:316–20

  • MF Holick
  • J Cell Biochem 2003;88:296–307
  • 2003

Similar Papers

Loading similar papers…